#	Pagina
attuale pagina	/open-h2020/projects/204375/index.html

Opendata, web and dolomites

BloodStemPLUS

Commercial feasibility study of a technology that multiplies blood stem cells to increase the success of transplants for cancer treatment

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

BloodStemPLUS project word cloud

Explore the words cloud of the BloodStemPLUS project. It provides you a very rough idea of what is the project "BloodStemPLUS" about.

invest track billion 500 quality reimbursement compliance won published 34 cord demand policies cagr recognition donor optimal 4b cell outcomes clinical explore lack sales markets business death innovation horizon commercialisation multiplying global 20x biotechnology 2020 patient summit start proprietary nature scientific enormous strategic japan treatment validation market preparing usa solution banks stemcell2max marketing route acceptance 600m scarce multiplies transplantation trial purposes maintenance cells november owns transplants limitations record stem groups 33 compromise hospitals ing first award partnering assuring company expansion plan blood regulatory 15 protected requirements cancer 2015 limited investor strategy patients investable 12 multiplication

Project "BloodStemPLUS" data sheet

The following table provides information about the project.

Coordinator	GROWINGFORMULA LDA Organization address address: BIOCANT PARK NUCLEO 04, LOTE 02 city: CANTANHEDE postcode: 3060 197 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Portugal [PT]
Project website	http://www.stemcell2max.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2016-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GROWINGFORMULA LDA GROWINGFORMULA LDA Organization address address: BIOCANT PARK NUCLEO 04, LOTE 02 city: CANTANHEDE postcode: 3060 197 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (CANTANHEDE)	coordinator	50˙000.00

Map

Project objective

StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but are scarce resulting in limited transplants (34% of patients do not find a donor), patient death (6-15%) and limitations at research level (12.500 groups lack cells for their studies). StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers in an estimated €3 billion potential market (33% CAGR).

No solution for blood stem cell multiplication is available for clinical purposes and those that are currently used for research purposes compromise cell quality. StemCell2MAX has developed a product that multiplies these cells while assuring their quality (20x better results compared to state of the art, as published in Nature).

Currently, StemCell2MAX markets a research use only product (€600M market) with a growing sales track record, both in EU and USA. Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing their solution for the €2.4B clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX won the “most investable company” award during the first Horizon 2020 – Invest Horizon Global Investor Summit in November 2015.

Specific objectives: • To develop a business plan and marketing strategy for clinical application • To explore strategic partnerships for development and commercialisation • To explore the clinical validation strategy/clinical trial design • To develop a strategic development plan in agreement with reimbursement policies

Expected outcomes: • A business plan and optimal route-to-market, including partnering strategy for further development • Clinical trial strategy in compliance with all regulatory requirements

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLOODSTEMPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLOODSTEMPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination